219 related articles for article (PubMed ID: 16669957)
1. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK
Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
3. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
van Deventer SJ; Wedel MK; Baker BF; Xia S; Chuang E; Miner PB
Aliment Pharmacol Ther; 2006 May; 23(10):1415-25. PubMed ID: 16669956
[TBL] [Abstract][Full Text] [Related]
4. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
van Deventer SJ; Tami JA; Wedel MK
Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
[TBL] [Abstract][Full Text] [Related]
5. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
Miner P; Wedel M; Bane B; Bradley J
Aliment Pharmacol Ther; 2004 Feb; 19(3):281-6. PubMed ID: 14984374
[TBL] [Abstract][Full Text] [Related]
6. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
[TBL] [Abstract][Full Text] [Related]
7. Alicaforsen. Isis Pharmaceuticals.
Gewirtz AT; Sitaraman S
Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.
Vegter S; Tolley K; Wilson Waterworth T; Jones H; Jones S; Jewell D
Aliment Pharmacol Ther; 2013 Aug; 38(3):284-93. PubMed ID: 23750909
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: alicaforsen (Isis).
Gewirtz AT; Sitaraman SV
Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
[TBL] [Abstract][Full Text] [Related]
12. Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.
Greuter T; Vavricka SR; Biedermann L; Pilz J; Borovicka J; Seibold F; Sauter B; Rogler G
Dig Dis; 2018; 36(2):123-129. PubMed ID: 29207381
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis.
Sandborn WJ; Tremaine WJ; Schroeder KW; Steiner BL; Batts KP; Lawson GM
Am J Gastroenterol; 1993 May; 88(5):640-5. PubMed ID: 8480724
[TBL] [Abstract][Full Text] [Related]
14. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis.
Hammond A; Andus T; Gierend M; Ecker KW; Scholmerich J; Herfarth H;
Hepatogastroenterology; 2004; 51(59):1345-9. PubMed ID: 15362749
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
16. Alicaforsen for the treatment of inflammatory bowel disease.
Jairath V; Khanna R; Feagan BG
Expert Opin Investig Drugs; 2017 Aug; 26(8):991-997. PubMed ID: 28670932
[TBL] [Abstract][Full Text] [Related]
17. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
[TBL] [Abstract][Full Text] [Related]
18. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
19. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.
Leeds JM; Henry SP; Geary R; Burckin T; Levin AA
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):435-41. PubMed ID: 11198927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]